Cognitive Function After Radiation Therapy for Brain Tumours

University of Aarhus104 enrolled

Overview

This study will assess cognitive function in adult patients with a primary brain tumour treated with surgical resection with or without radiation therapy (RT). All types of brain tumours apart from glioblastoma will be included

RT to brain tumours causes cognitive dysfunction. The extent of RT induced changes in cognitive function and radio-sensitivity of the brain is unknown. RT with protons instead of photons spares the healthy brain tissue more and is believed to reduce the risk of cognitive dysfunction. There is modest knowledge on which parts of the brain the investigators need to spare, to prevent cognitive dysfunction. The study is a cross sectional study assessing cognitive function in patients with brain tumours previously treated with RT compared to a similar non irradiated group. 104 patients with specified brain tumours from Aarhus University Hospital treated in the period 2006-2016 will be included. The patients will do patient reported outcome (PRO) and undergo neuropsychological assessment with standardized tests: They will do this prior to RT treatment and ½, 1, 3 and 5 years afterwards. The PRO's included measures on quality of life, fatigue, sleep, depression, anxiety, and socio demografica. The standardized tests are: Trail making Test (TMT); Hopkins Verbal Learning Test (HVLT); Controlled Oral Word Association Test (COWAT) - Animals and S; Coding and Digit Span from WAIS-IV; Paced Auditory Serial Addition Test (PASAT). The correlation between cognitive scores and RT dose-volume parameters to specific areas in the brain will be tested.

Study Type

OBSERVATIONAL

Enrollment

104

Conditions

Primary Brain Tumor Radiation Toxicity

Interventions

Cognitive testingRADIATION

Patients will have their cognitive function tested by the use of standardized cognitive test and fill in questionnaires. Cognitive function will be assessed by standardized cognitive tests: Hopkins verbal learning test (HVLT), Trail Making Test part A and B (TMT A and TMT B), Pased Auditory Test (PASAT), Wechsler Adult Intelligence Scale coding and digit span (WAIS-IV), Controlled Oral Word Association Test (Cowat) and STROOP colour and word test (STROOP) Questionnaire include; Quality of life; EORTC QlQ-C30 (QlQ-C30), FACIT-Fatigue Scale (Version 4) (FACIT), Pittsburg Sleep Quality Index (PSQI), Hospital Anxiety and Depression Scale (HADS), Patient's Assessment of Own Functioning Inventory (PAOFI).

Eligibility

Sex: ALLMin age: 18 YearsMax age: 100 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * The participant must be 18 years or older and Danish speaking. * Performance status 0-2 * Capable of cooperating on testing * Diagnosed with one of the following diagnoses according to WHO 2016 classification 16 and been treated between 2006 and 2016 1. ZM93803 glioma (exclusive glioblastoma) 2. ZM9401/3 anaplastic astrocytoma, IDH mutant 3. ZM9400/3 diffuse astrocytoma, IDH-mutant 4. ZM9411/3 gemistocytisk astrocytoma, IDH mutant 5. ZM9400/3 diffuse astrocytoma, NOS 6. ZM9451/3 anaplastic oligodendroglioma, IDH mutant and 1p/19q-co deleted 7. ZM9450/3 oligodendroglioma, IDH mutant and 1p/19q-co deleted 8. ZM9450/3 oligodendroglioma, NOS 9. ZM9451/3 anaplastic oligodendroglioma, NOS 10. ZM9530/0 meningioma 11. ZM9470/3 medulloblastoma, NOS 12. DD352A pituitary adenoma 13. Other rare brain tumours including skull base sarcomas \- Exclusion Criteria: Performance status 3-4 Progression after radiation therapy \-

Locations (1)

Aarhus University Hospital

Aarhus, Region Midt, Denmark

Outcomes

Primary Outcomes

Memory impairment (as assessed by the HVLT-r)

To examine the correlation between memory impairment (assessed by HVLT-r) and mean dose to the hippocampus.